SCHEMBL6288538

SCHEMBL6288538

Cc1nc(C)n2nc(-c3ccc(Br)cc3)nc(NCc3ccc(Cl)cc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.43
F2 P00734 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
GSK3B P49841 1/20 0.42
PDE5A O76074 1/20 0.41
RAB9A P51151 2/20 0.41
HSD17B10 Q99714 1/20 0.40
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6291866 0.89 GSK3B (0.50) MAPTF2MEN1KMT2AGAA
SCHEMBL6288696 0.88 GSK3B (0.43) MAPTF2GSK3BPDE5ARAB9A
SCHEMBL6291373 0.87 MAPT (0.46) MAPTF2MEN1KMT2AKDM4E
SCHEMBL6627740 0.87 GSK3B (0.44) MAPTF2MEN1KMT2AKDM4E
SCHEMBL6291831 0.82 MAPT (0.48) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6288572 0.81 TSHR (0.46) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6288383 0.81 MEN1 (0.44) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL6288568 0.79 GSK3B (0.47) MAPTKDM4EGAAHTTGSK3B
SCHEMBL6288637 0.75 KDM4E (0.45) MAPTMEN1KMT2AKDM4ETHRB
SCHEMBL5619875 0.68 EGFR (0.45) MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936609-B2 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-08-30 US disclosed
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2004-12-09 US disclosed
EP-1404677-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-07 EP disclosed
WO-2003000693-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors PDE3A, PDE2A, PDE4A MAPT 1159/4885F2 4366/4885MEN1 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.